Evidence map›Paper›PMID 35799072›Full record

ArticleDiscover oncology2022

Deciphering the role of miR-187-3p/LRFN1 axis in modulating progression, aerobic glycolysis and immune microenvironment of clear cell renal cell carcinoma.

Wenhao Xu, Wangrui Liu, Aihetaimujiang Anwaier, Xi Tian, Jiaqi Su, Guohai Shi, Shiyin Wei, Yuanyuan Qu, Hailiang Zhang, Dingwei Ye

Open access · goldAbstract read
In one paragraph

Article in Discover oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Targeting HDAC6 to Overcome Autophagy-Promoted Anti-Cancer Drug Resistance.International journal of molecular sciences · 2022
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Wenhao Xu *Department of Urology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Dong'an Road 270, Shanghai, 200032, People's Republic of China.
Wangrui Liu *Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, People's Republic of China.
Aihetaimujiang Anwaier *Department of Urology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Dong'an Road 270, Shanghai, 200032, People's Republic of China.
Xi TianDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Dong'an Road 270, Shanghai, 200032, People's Republic of China.
Jiaqi SuDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Dong'an Road 270, Shanghai, 200032, People's Republic of China.
Guohai ShiDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Dong'an Road 270, Shanghai, 200032, People's Republic of China.
Shiyin WeiAffiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, People's Republic of China. yjweishiyin@163.com.
Yuanyuan QuDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Dong'an Road 270, Shanghai, 200032, People's Republic of China. quyy1987@163.com.
Hailiang ZhangDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Dong'an Road 270, Shanghai, 200032, People's Republic of China. zhanghl918@163.com.
Dingwei YeDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Dong'an Road 270, Shanghai, 200032, People's Republic of China. dwyelie@163.com.
Fudan University Shanghai Cancer Center · CNAffiliated Hospital of Youjiang Medical University for Nationalities · CNShanghai Jiao Tong University · CN

Funding

"Eagle" Program of Shanghai Anticancer Association SHCY-JC-2021105Natural Science Foundation of Shanghai 20ZR1413100Shanghai Municipal Health Bureau 2020CXJQ03
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is one of the most common malignant genitourinary cancers with high recurrence risk worldwide. Recently, multi-omics data facilitate obtaining a molecular landscape of tumor development, and were implemented to affect pathogenesis, phenotype, and prognosis of ccRCC. In this study, after screening for differential expressed microRNAs based on multiply datasets, we tested expression levels and prognostic value of miR-187-3p in ccRCC samples, and transfected miR-187-3p mimics or negative controls into ccRCC cells. Up-regulation of miR-187-3p restrains proliferation, migration and promotes apoptosis ability in human ccRCC A498 and 786O cells. In addition, Luciferase reporter assay revealed that miR-187-3p directly targets LRFN1-3'-UTR and negatively modulates LRFN1 expression. LRFN1 rescues proliferation and invasion capacities after miR-187-3p mimic transfection in vitro and in subcutaneous xenograft models. We further performed deep-sequencing technology and bioinformatics analyses to evaluate the biological functions and potential clinical implications of LRFN1 expression in ccRCC. Interestingly, LRFN1 could serve as an independent and potential biomarker for prognosis in over 1000 patients with ccRCC from multiply independent cohorts. Besides, the up-regulated LRFN1 expression prominently promoted intra-tumoral heterogeneity and immune-infiltrating microenvironment, represented by elevated M2 macrophage infiltration, CD8

Indexed as

BiomarkerClear cell renal cell carcinomaIntra-tumoral heterogeneityLRFN1microRNAmiR-187-3pTumor microenvironment (TME)

Identifiers

PMID35799072
PMCPMC9263027
OpenAlexW4284880570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.